Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated radiotherapy followed by R-GemOx plus PD-1 antibody in primary refractory DLBCL
ChiCTR2200060059Phase 2Recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, gemcitabine, oxaliplatin and PD-1 Monoclonal Antibody in diffuse large B-cell lymphoma (DLBCL), sponsored by Fujian Medical University Union Hospital. Primary endpoint: Complete remission rate. Started May 2022; status: recruiting.
02
Drugs
rituximabgemcitabineoxaliplatinPD-1 Monoclonal Antibody
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2200060059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060059.